Adverum Biotechnologies, Inc.

Equities

ADVM

US00773U2078

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:32:34 2024-05-20 EDT			5-day change	1st Jan Change
8.25 ^USD	+2.61%		-9.65%	+10.06%

05-16	Transcript : Adverum Biotechnologies, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM
05-09	Adverum Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

May 25, 2023 at 06:29 am

On May 22, 2023, Adverum Biotechnologies, Inc. and Richard Beckman, M.D., Adverum's Chief Medical Officer, agreed that Dr. Beckman would resign as the Company's Chief Medical Officer, effective June 1, 2023.

Latest news about Adverum Biotechnologies, Inc.

Transcript : Adverum Biotechnologies, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM	05-15
Adverum Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target	04-30	MT
Mizuho Adjusts Price Target on Adverum Biotechnologies to $22 From $40 After Model Update, Maintains Buy Rating	04-29	MT
Adverum Biotechnologies Files $200 Million Mixed Shelf	03-21	MT
RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk	03-19	MT
Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Adverum Biotechnologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-18	CI
Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors	02-20	CI
Transcript : Adverum Biotechnologies, Inc. - Special Call	02-08
Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD	02-08	CI
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	02-05	RE
Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors	02-04	CI
Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee	01-29	CI
Adverum Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors	11-06	CI
Adverum Biotechnologies Announces Three-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023	11-04	CI
Mizuho Starts Adverum Biotechnologies With Buy Rating, Price Target is $2	11-02	MT
Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial	23-09-26	CI
Adverum Biotechnologies Names R. Andrew Ramelmeier Chief Technology Officer	23-08-22	MT
Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer	23-08-21	CI
North American Morning Briefing : Stock Futures -2-	23-08-14	DJ
Sector Update: Health Care Stocks Steady Premarket Friday	23-08-11	MT
Chardan Upgrades Adverum Biotechnologies to Buy From Neutral, Expecting Positive Outcome From Ongoing LUNA Trial, Raises Price Target to $4 From $2	23-08-11	MT
Adverum Biotechnologies Completes Enrollment in Mid-Stage Wet AMD Trial, Narrows Q2 Loss	23-08-10	MT

Chart Adverum Biotechnologies, Inc.

Duration

Period

More charts

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.

Sector

Biotechnology & Medical Research

Calendar

11:00am - H.C. Wainwright BioConnect Investor Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Adverum Biotechnologies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.04 USD

Average target price

35.33 USD

Spread / Average Target

+339.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADVERUM BIOTECHNOLOGIES, INC.	+10.06%	167M
VERTEX PHARMACEUTICALS INCORPORATED	+9.66%	115B
REGENERON PHARMACEUTICALS, INC.	+11.72%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-13.27%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.90%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+6.37%	14.32B
SAREPTA THERAPEUTICS, INC.	+33.94%	12.42B

Bio Therapeutic Drugs